Position Paper: Ipecac Syrup

References

• Arnold F J, Hodges J B, Jr, Barta R A, Jr. Evaluation of the efficacy of lavage and induced emesis in treatment of salicylate poisoning. Pediatrics 1959; 23: 286–301
   PubMed Web of Science ®Google Scholar
• Abdallah A H, Tye A. A comparison of the efficacy of emetic drugs and stomach lavage. Am J Dis Child 1967; 113: 571–575
   PubMedGoogle Scholar
• Corby D G, Lisciandro R C, Lehman R H, Decker W J. The efficiency of methods used to evacuate the stomach after acute ingestions. Pediatrics 1967; 40: 871–874
   PubMed Web of Science ®Google Scholar
• Teshima D, Suzuki A, Otsubo K, et al. Efficacy of emetic and United States Pharmacopoeia ipecac syrup in prevention of drug absorption. Chem Pharm Bull 1990; 38: 2242–2245
   PubMed Web of Science ®Google Scholar
• Neuvonen P J, Vartiainen M, Tokola O. Comparison of activated charcoal and ipecac syrup in prevention of drug absorption. Eur J Clin Pharmacol 1983; 24: 557–562
   PubMed Web of Science ®Google Scholar
• Curtis R A, Barone J, Giacona N. Efficacy of ipecac and activated charcoal/cathartic. Arch Intern Med 1984; 144: 48–52
   PubMed Web of Science ®Google Scholar
• Neuvonen P J, Olkkola K T. Activated charcoal and syrup of ipecac in prevention of cimetidine and pindolol absorption in man after administration of metoclopramide as an antiemetic agent. J Toxicol Clin Toxicol 1984; 22: 103–114
   PubMed Web of Science ®Google Scholar
• Tandberg D, Diven B G, McLeod J W. Ipecac‐induced emesis versus gastric lavage. Am J Emerg Med 1986; 4: 205–209
   PubMed Web of Science ®Google Scholar
• Tenenbein M, Cohen S, Sitar D S. Efficacy of ipecac‐induced emesis, orogastric lavage, and activated charcoal for acute drug overdose. Ann Emerg Med 1987; 16: 838–841
   PubMed Web of Science ®Google Scholar
• Danel V, Henry J A, Glucksman E. Activated charcoal, emesis, and gastric lavage in aspirin overdose. BMJ 1988; 296: 1507
   PubMed Web of Science ®Google Scholar
• Vasquez T E, Evans D G, Ashburn W L. Efficacy of syrup of ipecac‐induced emesis for emptying gastric contents. Clin Nucl Med 1988; 13: 638–639
   PubMed Web of Science ®Google Scholar
• McNamara R M, Aaron C K, Gemborys M, Davidheiser S. Efficacy of charcoal cathartic versus ipecac in reducing serum acetaminophen in a simulated overdose. Ann Emerg Med 1989; 18: 934–938
   PubMed Web of Science ®Google Scholar
• Tandberg D, Murphy L C. The knee‐chest position does not improve the efficacy of ipecac‐induced emesis. Am J Emerg Med 1989; 7: 267–270
   PubMed Web of Science ®Google Scholar
• Young W F, Bivins H G. Evaluation of gastric emptying using radionuclides: gastric lavage versus ipecac‐induced emesis. Ann Emerg Med 1993; 22: 1423–1427
   PubMed Web of Science ®Google Scholar
• Saincher A, Sitar D S, Tenenbein M. Efficacy of ipecac during the first hour after drug ingestion in human volunteers. J Toxicol Clin Toxicol 1997; 35(6)609–615
   PubMed Web of Science ®Google Scholar
• Bond G R, Requa R K, Krenzelok E P, et al. Influence of time until emesis on the efficacy of decontamination using acetaminophen as a marker in a pediatric population. Ann Emerg Med 1993; 22: 1403–1407
   PubMed Web of Science ®Google Scholar
• Kulig K, Bar‐Or D, Cantrill S V, Rosen P, Rumack B H. Management of acutely poisoned patients without gastric emptying. Ann Emerg Med 1985; 14: 562–567
   PubMed Web of Science ®Google Scholar
• Pond S M, Lewis‐Driver D J, Williams G M, Green A C, Stevenson N W. Gastric emptying in acute overdose: a prospective randomised controlled trial. Med J Aust 1995; 163: 345–349
   PubMed Web of Science ®Google Scholar
• Chafee‐Bahamon C, Lacouture P G, Lovejoy F H, Jr. Risk assessment of ipecac in the home. Pediatrics 1985; 75: 1105–1109
   PubMed Web of Science ®Google Scholar
• Litovitz T L, Klein‐Schwartz W, Oderda G M, et al. Ipecac administration in children younger than 1 year of age. Pediatrics 1985; 76: 761–764
   PubMed Web of Science ®Google Scholar
• Czajka P A, Russell S L. Nonemetic effects of ipecac syrup. Pediatrics 1985; 75: 1101–1104
   PubMed Web of Science ®Google Scholar
• Watson W A, Litovitz T L, Rodgers G C, et al. 2002 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003; 21: 353–421
   PubMed Web of Science ®Google Scholar
• Corby D G, Decker W J, Moran M J, Payne C E. Clinical comparison of pharmacologic emetics in children. Pediatrics 1968; 42: 361–364
   PubMed Web of Science ®Google Scholar
• Auerbach P S, Osterloh J, Braun O, et al. Efficacy of gastric emptying: gastric lavage versus emesis induced with ipecac. Ann Emerg Med 1986; 15: 692–698
   PubMed Web of Science ®Google Scholar
• Saetta J P, March S, Gaunt M E, Quinton D N. Gastric emptying procedures in the self‐poisoned patient: are we forcing gastric content beyond the pylorus?. J R Soc Med 1991; 84: 274–276
   PubMed Web of Science ®Google Scholar
• Merigian K S, Woodard M, Hedges J R, Roberts J R, Stuebling R, Rashkin M C. Prospective evaluation of gastric emptying in the self‐poisoned patient. Am J Emerg Med 1990; 8: 479–483
   PubMed Web of Science ®Google Scholar
• Kornberg A E, Dolgin J. Pediatric ingestions: charcoal alone versus ipecac and charcoal. Ann Emerg Med 1991; 20: 648–651
   PubMed Web of Science ®Google Scholar
• Bond G R. Home use of syrup of ipecac is associated with a reduction in pediatric emergency department visits. Ann Emerg Med 1995; 25: 338–343
   PubMed Web of Science ®Google Scholar
• Bond G R. Home syrup of ipecac use does not reduce emergency department use or improve outcome. Pediatrics 2003; 112: 1061–1064
   PubMed Web of Science ®Google Scholar
• Amitai Y, Mitchell A A, McGuigan M A, Lovejoy F H, Jr. Ipecac‐induced emesis and reduction of plasma concentrations of drugs following accidental overdose in children. Pediatrics 1987; 80: 364–367
   PubMed Web of Science ®Google Scholar
• Underhill T J, Greene M K, Dove A F. A comparison of the efficacy of gastric lavage, ipecacuanha and activated charcoal in the emergency management of paracetamol overdose. Arch Emerg Med 1990; 7: 148–154
   PubMedGoogle Scholar
• Saetta J P, Quinton D N. Residual gastric content after gastric lavage and ipecacuanha‐induced emesis in self‐poisoned patients: an endoscopic study. J R Soc Med 1991; 84: 35–38
   PubMed Web of Science ®Google Scholar
• Tenenbein M. Inefficacy of gastric emptying procedures. J Emerg Med 1985; 3: 133–136
   PubMedGoogle Scholar
• Peterson C D, Fifield G C. Emergency gastrotomy for acute iron poisoning. Ann Emerg Med 1980; 9: 262–264
   PubMed Web of Science ®Google Scholar
• Landsman I, Bricker J T, Reid B S, Bloss R S. Emergency gastrotomy: treatment of choice of iron bezoar. J Pediatr Surg 1987; 22: 184–185
   PubMed Web of Science ®Google Scholar
• Albertson T E, Derlet R W, Foulke G E, Minguillon M C, Tharratt S R. Superiority of activated charcoal alone compared with ipecac and activated charcoal in the treatment of acute toxic ingestions. Ann Emerg Med 1989; 18: 56–59
   PubMed Web of Science ®Google Scholar
• Wax P M, Cobaugh D J, Lawrence R A. Should home ipecac‐induced emesis be routinely recommended in the management of berry ingestions?. Vet Hum Toxicol 1999; 41(6)394–397
   PubMedGoogle Scholar
• Tanberg D, Liechty E J, Fishbein D. Mallory–Weiss Syndrome: an unusual complication of ipecac‐induced emesis. Ann Emerg Med 1981; 10: 521–523
   PubMed Web of Science ®Google Scholar
• Timberlake G A. Ipecac as a cause of the Mallory–Weiss Syndrome. Sooth Med J 1984; 77: 804–805
   PubMed Web of Science ®Google Scholar
• Wolowodiuk O K, McMicken D B, O'Brien P. Pneumomediastinum and retropneumoperitoneum: an unusual complication of syrup‐of‐ipecac‐induced emesis. Ann Emerg Med 1984; 13: 1148–1151
   PubMed Web of Science ®Google Scholar
• Wrenn K, Rodenwald L, Docstader L. Potential misuse of ipecac. Ann Emerg Med 1993; 22: 1408–1422
   PubMed Web of Science ®Google Scholar
• Robertson W O. Syrup of ipecac associated fatality: a case report. Vet Hum Toxicol 1979; 21: 87–89
   PubMedGoogle Scholar
• Klein‐Schwartz W, Gorman R L, Oderda G M, Wedin G P, Saggar D. Ipecac use in the elderly: the unanswered question. Ann Emerg Med 1984; 13: 1152–1154
   PubMed Web of Science ®Google Scholar
• Knight K M, Doucet H J. Gastric rupture and death caused by ipecac syrup. South Med J 1987; 80: 786–787
   PubMed Web of Science ®Google Scholar
• Adler A G, Walinsky P, Krall R A, Cho S Y. Death resulting from ipecac syrup poisoning. JAMA 1980; 243: 1927–1928
   PubMed Web of Science ®Google Scholar
• Robertson W O. Safety of ipecac syrup. JAMA 1980; 244: 1675
   PubMed Web of Science ®Google Scholar
• Brotman M C, Forbath N, Garfinkel P E, Humphrey J G. Myopathy due to ipecac syrup poisoning in a patient with anorexia nervosa. Can Med Assoc J 1981; 125: 453–454
   PubMed Web of Science ®Google Scholar
• Mateer J E, Farrell B J, Chou S S, Gutmann L. Reversible ipecac myopathy. Arch Neurol 1985; 42: 188–190
   PubMed Web of Science ®Google Scholar
• Bennett H S, Spiro A J, Pollack M A, Zucker P. Ipecac‐induced myopathy simulating dermatomyositis. Neurology 1982; 32: 91–94
   PubMed Web of Science ®Google Scholar
• Friedman E J. Death from ipecac intoxication in a patient with anorexia nervosa. Am J Psychiat 1984; 141: 702–703
   PubMed Web of Science ®Google Scholar
• Moldawsky R J. Myopathy and ipecac abuse in a bulimic patient. Psychosomatics 1985; 26: 448–449
   PubMed Web of Science ®Google Scholar
• Palmer E P, Guay A T. Reversible myopathy secondary to abuse of ipecac in patients with major eating disorders. N Engl J Med 1985; 313: 1457–1459
   PubMed Web of Science ®Google Scholar
• Dawson J A, Yager J. A case of abuse of syrup of ipecac resulting in death. J Am Coll Health 1986; 34: 280–282
   PubMedGoogle Scholar
• Rosenberg N L, Ringel S P. Myopathy from surreptitious ipecac ingestion. West J Med 1986; 145: 386–388
   PubMedGoogle Scholar
• Schiff R J, Wurzel C L, Brunson S C, Kasloff I, Nussbaum M P, Frank S D. Death due to chronic syrup of ipecac use in a patient with bulimia. Pediatrics 1986; 78: 412–416
   PubMed Web of Science ®Google Scholar
• Friedman A G, Seime R J, Roberts T, Fremouw W J. Ipecac abuse: a serious complication in bulimia. Gen Hosp Psychiat 1987; 9: 225–228
   PubMed Web of Science ®Google Scholar
• Halbig L, Gutmann L, Goebel H H, Brick J F, Schochet S. Ultrastructural pathology in emetine‐induced myopathy. Acta Neuropathol (Berl) 1988; 75: 577–582
   PubMed Web of Science ®Google Scholar
• Kuntzer T, Bogousslavsky J, Deruaz J P, Janzer R, Regli F. Reversible emetine‐induced myopathy with ECG abnormalities: a toxic myopathy. J Neurol 1989; 236: 246–248
   PubMed Web of Science ®Google Scholar
• Dresser L P, Massey E W, Johnson E E, Bossen E. Ipecac myopathy and cardiomyopathy. J Neurol Neurosurg Psychiat 1993; 56: 560–562
   PubMed Web of Science ®Google Scholar
• Thyagarajan D, Day B J, Wodak J, Gilligan B, Dennett X. Emetine myopathy in a patient with an eating disorder. Med J Aust 1993; 159: 757–760
   PubMed Web of Science ®Google Scholar
• Ho P C, Dweik R, Cohen M C. Rapidly reversible cardiomyopathy associated with chronic ipecac ingestion. Clin Cardiol 1998; 21: 780–783
   PubMed Web of Science ®Google Scholar
• Cooper C, Kilham H, Ryan M. Ipecac—a substance of abuse. Med J Aust 1998; 168: 94–95
   PubMed Web of Science ®Google Scholar
• McClung H J, Murray R, Braden N J, Fyda J, Myers R P, Gutches L. Intentional ipecac poisoning in children. Am J Dis Child 1988; 142: 637–639
   PubMedGoogle Scholar
• Berkner P, Kastner T, Skolnick L. Chronic ipecac poisoning in infancy: a case report. Pediatrics 1988; 82: 384–386
   PubMed Web of Science ®Google Scholar
• Sutphen J L, Saulsbury F T. Intentional ipecac poisoning: munchausen syndrome by proxy. Pediatrics 1988; 82: 453–456
   PubMed Web of Science ®Google Scholar
• Colletti R B, Wasserman R C. Recurrent infantile vomiting due to intentional ipecac poisoning. J Pediatr Gastroenterol Nutr 1989; 8: 394–396
   PubMed Web of Science ®Google Scholar
• Day L, Kelly C, Reed G, Andersen J M, Keljo J M. Fatal cardiomyopathy: suspected child abuse by chronic ipecac administration. Vet Hum Toxicol 1989; 31: 255–257
   PubMedGoogle Scholar
• Santangelo W C, Richey J E, Rivera L, Fordtran J S. Surreptitious ipecac administration simulating intestinal pseudo‐obstruction. Ann Intern Med 1989; 110: 1031–1032
   PubMed Web of Science ®Google Scholar
• Johnson J E, Carpenter B L, Benton J, Cross R, Eaton L A, Jr, Rhoads J M. Hemorrhagic colitis and pseudomelanosis coli in ipecac ingestion by proxy. J Pediatr Gastroenterol Nutr 1991; 12: 501–506
   PubMed Web of Science ®Google Scholar
• Goebel J, Gremse D A, Artman M. Cardiomyopathy from ipecac administration in Munchausen syndrome by proxy. Pediatrics 1993; 92: 601–603
   PubMed Web of Science ®Google Scholar
• Schneider D J, Perez A, Knilamus T E, Daniels S R, Bove K E, Bonnell H. Clinical and pathologic aspects of cardiomyopathy from ipecac administration in Munchausen's syndrome by proxy. Pediatrics 1996; 97: 902–906
   PubMed Web of Science ®Google Scholar